المؤلفون: Giaccone G; National Cancer Institute, Bethesda, MD, USA. Electronic address: gg496@georgetown.edu., Bazhenova LA; Moores Cancer Center, UC San Diego, La Jolla, CA, USA., Nemunaitis J; Mary Crowley Cancer Research Centers, Dallas, TX, USA., Tan M; Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USA., Juhász E; Korányi National Institute for TB and Pulmonology, Budapest, Hungary., Ramlau R; Wielkopolskie Centrum Pulmonologii i Torakochirurgii, Poznań University of Medical Sciences, Poznan, Poland., van den Heuvel MM; Netherlands Cancer Institute, Antoni Van Leeuwenhoek Hospital, Thoracic Oncology, Amsterdam, Netherlands., Lal R; Guy's Hospital, King's Health Partners, London, England, United Kingdom., Kloecker GH; James Graham Brown Cancer Center, University of Louisville, Louisville, KY, USA., Eaton KD; Seattle Cancer Care Alliance, University of Washington, Seattle, WA, USA., Chu Q; Cross Cancer Institute, Edmonton, Alberta, Canada., Dunlop DJ; Royal Infirmary, Glasgow, Scotland, United Kingdom., Jain M; Noble Hospital, Pune, India., Garon EB; University of California, Los Angeles, Los Angeles, CA, USA., Davis CS; CSD Biostatistics, Tucson, AZ, USA., Carrier E; NovaRx Corporation, San Diego, CA, USA., Moses SC; NovaRx Corporation, San Diego, CA, USA., Shawler DL; NovaRx Corporation, San Diego, CA, USA., Fakhrai H; NovaRx Corporation, San Diego, CA, USA.

المصدر: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2015 Nov; Vol. 51 (16), pp. 2321-9. Date of Electronic Publication: 2015 Aug 14.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Cancer Vaccines/*therapeutic use , Carcinoma, Non-Small-Cell Lung/*drug therapy , Lung Neoplasms/*drug therapy , Maintenance Chemotherapy/*methods, Adult ; Aged ; Cancer Vaccines/adverse effects ; Carcinoma, Non-Small-Cell Lung/immunology ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/pathology ; Disease Progression ; Disease-Free Survival ; Double-Blind Method ; Female ; Humans ; Intention to Treat Analysis ; Kaplan-Meier Estimate ; Lung Neoplasms/immunology ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Proportional Hazards Models ; Time Factors ; Treatment Outcome